Many Novo Nordisk are not even aware that the anti-obesity injection Saxenda is even on the market. The drug was launched just over a year ago, but talk about Saxenda is simply not a focal point ...

Novo already has one GLP-1 obesity drug on the market, Saxenda, launched in 2015, but with the introduction of Wegovy to the U.S. market, an overlap between patients could occur, it said.

Novo Nordisk A/S won approval of a weight-loss injection, adding to a list of pharmaceutical options for Americans attempting to shrink their waistlines. Novo Nordisk’s Saxenda was cleared for ...